Valuation: Dermapharm Holding SE

Market Cap 1.91B 2.13B 1.76B 1.59B 2.98B 203B 3.03B 20.94B 8.38B 106B 8B 7.83B 336B P/E 2026 *
14.7x
P/E 2027 * 13x
Enterprise Value 2.72B 3.04B 2.5B 2.27B 4.24B 289B 4.32B 29.84B 11.94B 152B 11.39B 11.15B 478B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.07x
Free-Float
10.7%
Yield 2026 *
2.65%
Yield 2027 * 2.96%
1 week-0.39%
Current month-1.66%
1 month-1.28%
3 months-10.04%
6 months-16.29%
Current year-2.03%
1 week 37.8
Extreme 37.8
38.95
1 month 37.35
Extreme 37.35
39.1
Current year 34.3
Extreme 34.3
51.9
1 year 32.9
Extreme 32.9
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/5/26 Buy

Chairman

380,000 0.7670%
7/1/26 Buy 150 0.0003%
7/1/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.39%+15.42%+4.36% 2.13B
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.88%+2.29%+44.54%+77.09% 417.9B
Weighted average by Cap. +1.97%+3.04%+53.33%+100.37%

Financials

2026 *2027 *
Net sales 1.21B 1.35B 1.11B 1.01B 1.88B 128B 1.92B 13.25B 5.3B 67.34B 5.06B 4.95B 212B 1.25B 1.4B 1.15B 1.05B 1.96B 133B 1.99B 13.75B 5.5B 69.9B 5.25B 5.14B 221B
Net income 137M 153M 126M 114M 214M 14.56B 218M 1.5B 602M 7.65B 575M 562M 24.13B 155M 173M 143M 129M 242M 16.48B 246M 1.7B 682M 8.65B 650M 636M 27.31B
Net Debt 812M 906M 747M 676M 1.27B 86.1B 1.29B 8.9B 3.56B 45.23B 3.4B 3.33B 143B 687M 766M 632M 572M 1.07B 72.85B 1.09B 7.53B 3.01B 38.27B 2.88B 2.81B 121B
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
30/10/26 EUR 38.55 0.00% 5,424
29/10/26 EUR 38.55 +0.92% 17,671
28/10/26 EUR 38.20 -0.52% 15,757
27/10/26 EUR 38.40 +1.45% 11,217
26/10/26 EUR 37.85 -1.43% 10,131
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.55EUR
Average target price
51.00EUR
Spread / Average Target
+32.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE